Published in Prog Retin Eye Res on October 20, 2016
Detection of Functional Change Using Cluster Trend Analysis in Glaucoma. Invest Ophthalmol Vis Sci (2017) 0.75
Global data on visual impairment in the year 2002. Bull World Health Organ (2004) 28.05
The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol (2006) 25.47
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
Number of people with glaucoma worldwide. Br J Ophthalmol (1996) 14.31
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (2002) 14.17
The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol (2000) 12.21
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol (2003) 8.76
Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol (1998) 7.34
Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology (2001) 6.82
The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol (1998) 6.70
Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol (2004) 5.44
Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology (2007) 4.79
A framework for comparing structural and functional measures of glaucomatous damage. Prog Retin Eye Res (2007) 4.64
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet (2014) 3.93
Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA (2014) 3.85
Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res (1993) 3.28
Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol (2008) 3.25
A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol (1991) 3.23
Normal variability of static perimetric threshold values across the central visual field. Arch Ophthalmol (1987) 3.22
Changing views on open-angle glaucoma: definitions and prevalences--The Rotterdam Study. Invest Ophthalmol Vis Sci (2000) 3.19
Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology (2004) 3.14
Natural history of open-angle glaucoma. Ophthalmology (2009) 2.99
Results of the European Glaucoma Prevention Study. Ophthalmology (2005) 2.91
Early detection of visual field progression in glaucoma: a comparison of PROGRESSOR and STATPAC 2. Br J Ophthalmol (1997) 2.88
Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol (2001) 2.84
Cost-effectiveness of treating ocular hypertension. Ophthalmology (2008) 2.74
Glaucomatous damage of the macula. Prog Retin Eye Res (2012) 2.70
Expert agreement in evaluating the optic disc for glaucoma. Ophthalmology (1992) 2.58
The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology (2009) 2.57
Intraobserver and interobserver agreement in measurement of optic disc characteristics. Ophthalmology (1988) 2.54
Test-retest variability in glaucomatous visual fields. Am J Ophthalmol (1989) 2.40
Association between rates of binocular visual field loss and vision-related quality of life in patients with glaucoma. JAMA Ophthalmol (2013) 2.37
Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol (1997) 2.31
Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology (2006) 2.28
The probability of blindness from open-angle glaucoma. Ophthalmology (1998) 2.28
Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology (2008) 2.20
Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol (2010) 2.14
The rate of progression of scotomas in glaucoma. Am J Ophthalmol (1986) 2.13
Quality of life in glaucoma and its relationship with visual function. J Glaucoma (2003) 2.13
Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime. Invest Ophthalmol Vis Sci (2014) 2.12
The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol (1995) 2.10
Severity of visual field loss and health-related quality of life. Am J Ophthalmol (2007) 2.05
Glaucoma Progression Analysis software compared with expert consensus opinion in the detection of visual field progression in glaucoma. Ophthalmology (2011) 2.01
Regression analysis of visual field progression in low tension glaucoma. Br J Ophthalmol (1991) 1.96
Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand (2003) 1.96
Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol (2011) 1.85
The structure and function relationship in glaucoma: implications for detection of progression and measurement of rates of change. Invest Ophthalmol Vis Sci (2012) 1.83
Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci (2007) 1.83
Pointwise univariate linear regression of perimetric sensitivity against follow-up time in glaucoma. Ophthalmology (1997) 1.80
Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol (2006) 1.80
Frequency of testing for detecting visual field progression. Br J Ophthalmol (2002) 1.77
Test-retest variability of frequency-doubling perimetry and conventional perimetry in glaucoma patients and normal subjects. Invest Ophthalmol Vis Sci (1999) 1.68
Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci (1996) 1.67
Relationship between severity of visual field loss at presentation and rate of visual field progression in glaucoma. Ophthalmology (2010) 1.64
Identifying areas of the visual field important for quality of life in patients with glaucoma. PLoS One (2013) 1.63
Modelling series of visual fields to detect progression in normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol (1995) 1.56
Repeatability of automated perimetry: a comparison between standard automated perimetry with stimulus size III and V, matrix, and motion perimetry. Invest Ophthalmol Vis Sci (2008) 1.52
Signal/noise analysis to compare tests for measuring visual field loss and its progression. Invest Ophthalmol Vis Sci (2009) 1.51
Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol (2011) 1.51
Early glaucoma involves both deep local, and shallow widespread, retinal nerve fiber damage of the macular region. Invest Ophthalmol Vis Sci (2014) 1.47
Initial parafoveal versus peripheral scotomas in glaucoma: risk factors and visual field characteristics. Ophthalmology (2011) 1.45
The mode of progression of visual field defects in glaucoma. Am J Ophthalmol (1984) 1.45
Variability components of standard automated perimetry and frequency-doubling technology perimetry. Invest Ophthalmol Vis Sci (2001) 1.42
Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol (2002) 1.41
Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol (2004) 1.41
Prevalence and nature of early glaucomatous defects in the central 10° of the visual field. JAMA Ophthalmol (2014) 1.39
Peripheral vision and pattern recognition: a review. J Vis (2011) 1.36
Test-retest variability in glaucomatous visual fields. Am J Ophthalmol (1990) 1.35
Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol (2010) 1.34
Identification of progressive glaucomatous visual field loss. Surv Ophthalmol (2002) 1.33
The use of visual field indices in detecting changes in the visual field in glaucoma. Invest Ophthalmol Vis Sci (1990) 1.32
The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol (2002) 1.32
The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci (2009) 1.31
Measurement of quality of life: current state of the art. Arch Phys Med Rehabil (1982) 1.30
Variability in patients with glaucomatous visual field damage is reduced using size V stimuli. Invest Ophthalmol Vis Sci (1997) 1.29
Importance of visual acuity and contrast sensitivity in patients with glaucoma. Arch Ophthalmol (2010) 1.27
Prediction of glaucomatous visual field loss by extrapolation of linear trends. Arch Ophthalmol (2009) 1.25
Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. J Glaucoma (2008) 1.24
Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology (2005) 1.21
Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma. Trans Am Ophthalmol Soc (1996) 1.21
Visual field progression differences between normal-tension and exfoliative high-tension glaucoma. Invest Ophthalmol Vis Sci (2009) 1.19
Assessment of the reliability of standard automated perimetry in regions of glaucomatous damage. Ophthalmology (2014) 1.18
Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am J Ophthalmol (2012) 1.18
Estimating progression of visual field loss in glaucoma. Ophthalmology (1997) 1.16
Characteristics of frequency-of-seeing curves in normal subjects, patients with suspected glaucoma, and patients with glaucoma. Invest Ophthalmol Vis Sci (1993) 1.15
Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance. Drug Saf (2013) 1.13
Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). J Glaucoma (2001) 1.13
Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol (2007) 1.12
The times they are a-changin': time to change glaucoma management. Acta Ophthalmol (2012) 1.11
Prediction of visual field progression in glaucoma. Invest Ophthalmol Vis Sci (2004) 1.11
Patterns of glaucomatous visual field progression identified by three progression criteria. Am J Ophthalmol (2004) 1.11
Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol (2002) 1.10
Regression analysis of the central visual field in chronic glaucoma cases. A follow-up study using automatic perimetry. Acta Ophthalmol (Copenh) (1982) 1.10
Age-related changes in the central visual field for short-wavelength-sensitive pathways. J Opt Soc Am A (1988) 1.10
Visual field index rate and event-based glaucoma progression analysis: comparison in a glaucoma population. Br J Ophthalmol (2009) 1.09
The effective dynamic ranges of standard automated perimetry sizes III and V and motion and matrix perimetry. Arch Ophthalmol (2010) 1.07
The SITA perimetric threshold algorithms in glaucoma. Invest Ophthalmol Vis Sci (1999) 1.07
Simulation of longitudinal threshold visual field data. Invest Ophthalmol Vis Sci (2000) 1.03
Lifetime risk of blindness in open-angle glaucoma. Am J Ophthalmol (2013) 1.03